InMed Pharmaceuticals (NASDAQ:INM) Stock: Insider
InMed Pharmaceuticals has seen a notable surge in 100% net open-market insider buying—with zero recorded insider sales over the past year.
Key institutional 10% owners, including ADAR1 Capital Management and Dr. Daniel Schneeberger, have consistently accumulated shares, with recent filings showing multi-tranche purchases at market prices around $1.29–$1.35 per share.
Key Insider Transactions
Heavy Accumulation by Major Holders: Over the past year, insiders have executed over 150 open-market transactions, purchasing roughly $3.6 million worth of INM shares with zero insider selling.
Consistent Open-Market Accumulation: Recent SEC Form 4 filings highlight continuous buying activity by 10% owners across small-to-mid block purchases:
ADAR1 Capital Management, LLC: Executed multiple tranches totaling tens of thousands of shares in late September and October.
Dr. Daniel Schneeberger: Accumulated significant blocks (including $100K+ purchases in September).
---
What Is Driving the Buying Signal?
Insider purchases, particularly from major institutional owners on the board or holding significant stakes, typically signal strong internal confidence in a company's fundamental catalysts or underlying valuation gap.
| Catalyst / Factor | Market Context & Signal |
| --- | --- |
| Pipeline & Pipeline Synergies | Following the strategic merger with Mentari Therapeutics and ongoing clinical programs targeting Alzheimer's, ocular, and dermatological indications, major owners are positioning for key clinical milestones. |
| Valuation Disconnect | Trading near micro-cap market valuations ($7M cap) with a stock price hovering around $1.30, 10% owners are aggressively buying shares below prior multi-month highs. |
| Nasdaq Equity Compliance | InMed recently addressed Nasdaq minimum shareholders' equity notifications, a key corporate governance concern that major investors monitor closely. |
---
Investor Playbook: How to Interpret Micro-Cap Insider Signals
1. Distinguish Between Insiders: Purchases by 10% hedge fund owners (like ADAR1) often reflect institutional position building or capital structure support, whereas purchases directly by executive management (CEO/CFO) reflect direct operational confidence.
2. Watch Key Technical & Regulatory Levels: For micro-cap stocks trading under $2.00, monitor progress toward maintaining Nasdaq listing requirements alongside clinical data readouts.
3. Assess Liquidity Risk: Given the lower daily trading volume typical of micro-cap biotech stocks, institutional insider support provides downside stability, but high price volatility remains present.